Back to List View Graph View

Cetuximab

Cetuximab (Erbitux) is a recombinant chimeric IgG1 monoclonal antibody directed at the extracellular domain of the EGFR, a receptor tyrosine kinase overexpressed or dysregulated in many solid tumors.

Where the papers sit

10 papers from the last 6 months study cetuximab directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 4 observational · 2 human data · 3 preclinical · 1 unclassified

Themes 3 themes

  • Colorectal Cancer Treatment

    Colorectal cancer therapy is being assessed through treatment safety, resistance biology, prognosis, access, and cost. Targeted therapy combined with FOLFOX or FOLFIRI generates adverse-event signals, while ZDHHC9-driven lipid reprogramming and ACSL3 palmitoylation emerge as mechanisms of cetuximab resistance. Tumor-educated platelet signatures aim to improve outcome prediction, and encorafenib is evaluated for the economic management of BRAF V600E-mutant disease. Treatment delivery also remains important, with chemoport-related venous stenosis documented as a complication.

    5 papers · 50%

  • Head and Neck Cancer Therapy

    Head and neck squamous cell carcinoma treatment is moving across neoadjuvant chemotherapy, real-world sequencing, immunotherapy, and targeted resistance management. Paclitaxel, carboplatin, and cetuximab are being tested before definitive treatment, while pembrolizumab features in recurrent or metastatic treatment pathways. An EGFR S442 ectodomain mutation confers cetuximab resistance, with trastuzumab-deruxtecan offering a potential ERBB2-directed rescue strategy. Photoimmunotherapy also remains an emerging treatment area requiring practical photosensitivity assessment.

    4 papers · 40%

  • α-Gal Allergy Antibody Therapy

    α-Gal allergy research is focusing on antibody control of allergen-driven IgE responses. Human monoclonal antibodies targeting α-Gal can restrict IgE engagement with α-Gal-containing allergens. The proposed effect is reduced activation of basophils and other allergic effector pathways. This work supports antibody-based strategies for limiting α-Gal syndrome, but clinical therapeutic benefit remains to be established.

    1 papers · 10%

Papers

The 10 papers from the last 6 months that study cetuximab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Colorectal Cancer Treatment (5)
  1. Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study. Medicine · 6 Nov 2026 PMID 42994833
  2. ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
  3. Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response. iScience · 30 Jun 2026 PMID 42375537
  4. Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China. The pharmacogenomics journal · 25 May 2026 PMID 42185244
  5. Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. PloS one · 20 May 2026 PMID 42160312
Head and Neck Cancer Therapy (4)
  1. Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study). Oral oncology · 18 Aug 2026 PMID 42612404
  2. Utility of a Simplified Irradiator for Photosensitivity Testing in Head and Neck Photoimmunotherapy. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379786
  3. Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
  4. EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
α-Gal Allergy Antibody Therapy (1)
  1. Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. The Journal of clinical investigation · 1 Sept 2026 PMID 42677844

By study type

Observational studies and case reports (4)
  1. Real-world treatment sequences and outcomes in recurrent/metastatic head and neck squamous cell carcinoma in France (TERENCE study). Oral oncology · 18 Aug 2026 PMID 42612404
  2. Utility of a Simplified Irradiator for Photosensitivity Testing in Head and Neck Photoimmunotherapy. In vivo (Athens, Greece) · 30 Jun 2026 PMID 42379786
  3. Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
  4. Chemoport-related right innominate vein stenosis in patients with colorectal cancer: A retrospective risk factor analysis. PloS one · 20 May 2026 PMID 42160312
Human data, design not indexed (2)
  1. Adverse event signals associated with targeted therapy plus chemotherapy in colorectal cancer: A FAERS-based pharmacovigilance study. Medicine · 6 Nov 2026 PMID 42994833
  2. Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China. The pharmacogenomics journal · 25 May 2026 PMID 42185244
Preclinical: animal, cell and lab studies (3)
  1. ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
  2. Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens. The Journal of clinical investigation · 1 Sept 2026 PMID 42677844
  3. EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
Unclassified: not yet indexed with MeSH (1)
  1. Machine learning algorithms develop a tumor-educated platelets-related gene signature to predict colorectal cancer prognosis and therapy response. iScience · 30 Jun 2026 PMID 42375537